Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pembrolizumab in Recurrent Respiratory Papillomatosis
NCT02632344Phase 2Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Apr 2016
- Primary completion
- Feb 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in recurrent respiratory papillomatosis (RRP), sponsored by Massachusetts General Hospital. Started Apr 2016; status: completed.
02
Drugs
03
Conditions
recurrent respiratory papillomatosis (RRP)
Beyond the preview
Go deeper on NCT02632344.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02632344.